Investment Rating - The report maintains a "Recommended" rating for the company [1][5]. Core Insights - The company reported a revenue of 1.247 billion yuan for the first half of 2025, a year-on-year decrease of 3.64%, while the net profit attributable to shareholders increased by 10.01% to 445 million yuan [3]. - The gross profit margin and net profit margin improved significantly, reaching 51.26% and 35.97% respectively, with increases of 3.78 percentage points and 4.32 percentage points year-on-year, driven by higher contributions from high-margin businesses in life sciences, metal resources, and ultra-pure water [3]. - The company plans to invest 1.15 billion yuan in building a high-end materials industrial park in Pucheng to enhance its life sciences segment [3]. Financial Performance Summary - For the first half of 2025, the company achieved a net cash flow of 288 million yuan, reflecting a positive trend [3]. - The company’s asset-liability ratio stood at 36.30%, a decrease of 3.73 percentage points year-on-year, indicating low debt risk [3]. - The company’s revenue from adsorption materials was 1.007 billion yuan, a year-on-year increase of 3.40%, with significant growth in the water treatment, life sciences, and metal resources segments [3]. Future Projections - The company is projected to achieve net profits of 1.014 billion yuan, 1.209 billion yuan, and 1.527 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 26.98X, 22.63X, and 17.92X [5][4]. - Revenue is expected to grow at rates of 17.66%, 22.90%, and 17.27% for the years 2025, 2026, and 2027 respectively [4][7].

公司高毛利业务占比提升，叠加原材料价格回落，推动公司毛利率增长 2025H1，公司吸附材料销售3.34 万吨，同比+8.35%；综合毛利率51.26%，同比+3.8pcts；其中吸附材料 毛利率为54.27%，同比+3.2 pcts。2025H1，公司生命科学板块营收同比+12.43%，其中多肽固相合成载 体业务延续良好增长态势；金属资源板块营收同比+22.84%，其中提镍、提稼、提铀等产品销售持续增 长；水处理板块营收同比+11.25%，其中高端饮用水与头部客户形成长单合同、超纯水在半导体、面板 等领域持续突破。据百川盈孚数据，2025 年H1 苯乙烯均价8,074元/吨，同比-13.06%。高毛利业务增 长、原材料价格回落，公司毛利率增长。 高毛利业务推动业绩增长，规划新产能有望助力成长，维持"买入"评级 据公司公告，2025 年H1 公司实现营收12.47 亿元，同比-3.64%；归母净利润4.45亿元，同比+10%；Q2 实现营收6.71 亿元，同比+1%，环比+16%；归母净利润2.51 亿元，同比+7%，环比+30%。公司盐湖提 锂大项目无收入确认拖累营收增长，但生命科学等高毛利业务占比提升、原材 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's high-margin business is driving performance growth, and the planned new capacity is expected to support future growth [5] - In H1 2025, the company achieved revenue of 1.247 billion yuan, a year-on-year decrease of 3.64%, while net profit attributable to the parent company was 445 million yuan, an increase of 10% year-on-year [5] - The company is expected to benefit from the production of its high-end materials industrial park in the life sciences sector, which is projected to enhance growth [7] Financial Performance Summary - In H1 2025, the company sold 33,400 tons of adsorption materials, a year-on-year increase of 8.35%, with a comprehensive gross margin of 51.26%, up 3.8 percentage points year-on-year [6] - The life sciences segment saw a revenue increase of 12.43% year-on-year, while the metal resources segment grew by 22.84% [6] - The company expects net profits for 2025-2027 to be 952 million yuan, 1.195 billion yuan, and 1.534 billion yuan respectively, with corresponding EPS of 1.88, 2.35, and 3.02 yuan [5][8] Future Growth Potential - The company plans to invest 1.15 billion yuan to build a high-end materials industrial park for life sciences, which is expected to drive future growth [7] - The company is expanding its global marketing and technical service network to support the development of its life sciences segment [7]

Group 1: Financial Performance - In 2024, the revenue from the system device business increased by 85%, but installation and debugging costs accounted for over 25% of the revenue [4] - The revenue from the life sciences sector reached 5.68 billion yuan, with a growth rate of 28% [14] - The revenue from the water treatment and ultrapure water business grew by 20%, with a total revenue of 6.88 billion yuan [7] Group 2: Operational Efficiency - The inventory turnover days extended to 180 days due to increased stock of system devices [4] - The company aims to reduce work-in-progress inventory by 25% through digital twin technology optimization [4] - The company achieved a 5-fold increase in inspection efficiency by replacing manual visual inspection with AI visual detection [3] Group 3: Market Expansion and Strategy - In 2024, overseas revenue accounted for 38% of total revenue, amounting to 6.55 billion yuan [10] - The company plans to enhance market development efficiency through the release of industry solution white papers covering six major fields [5] - The life sciences sector's revenue share increased to 29%, with a focus on new product development in peptide synthesis [5] Group 4: Research and Development - The R&D investment intensity reached 9.8%, but the patent implementation rate was below 45% [9] - The company holds 66 domestic and 13 foreign authorized patents, with 74 domestic and 103 foreign patents in the application stage [9] - The company is focusing on developing new types of polyethylene glycol carriers to increase drug loading capacity by 20% [5] Group 5: Supply Chain and Risk Management - The company reported no supply chain security challenges, with most raw materials already localized [12] - The accounts receivable turnover days extended to 125 days, with 65% of accounts receivable from system device projects [10] - The company is exploring credit insurance to cover 80% of accounts receivable to improve cash flow [10]